Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron D Berger

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Frontiers in Bioscience : a Journal and Virtual Library|May 25, 2006
Novel mutations of epidermal growth factor receptor in localized prostate cancerDiah A Douglas, Hong Zhong, Jae Y Ro, et al.
American Journal of Translational Research|December 8, 2009
Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHALonggui Wang, Xuanyi Zou, Aaron D Berger, et al.
Prostate Cancer and Prostatic Diseases|September 22, 2025
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patientsNeal D Shore, Christopher M Pieczonka, Sean Heron, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Frontiers in Bioscience : a Journal and Virtual Library|May 25, 2006
Novel mutations of epidermal growth factor receptor in localized prostate cancerDiah A Douglas, Hong Zhong, Jae Y Ro, et al.
American Journal of Translational Research|December 8, 2009
Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHALonggui Wang, Xuanyi Zou, Aaron D Berger, et al.
Prostate Cancer and Prostatic Diseases|September 22, 2025
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patientsNeal D Shore, Christopher M Pieczonka, Sean Heron, et al.
Pageof 2